Our 2025 study in JMIR Formative Research examined 12-month outcomes for participants using semaglutide with behavioural support and found 1 : 19.1% average weight loss at 12 months for active subscribers 77.7% achieved at least 10% weight loss 61.5% achieved at least 15% weight loss 69% reported no side effects by month 12 These are completer results (people who stayed on the programme for 12 months), not intent-to-treat
Regland B, Forsmark S, Halaouate L, Matousek M, Peilot B, Zachrisson O, et al
For instance, a growth-hormone releasing peptide may increase IGF-1 and promote follicular development, while a repair peptide decreases local inflammation and promotes tissue remodeling, synergistically enhancing the implantation milieu
For many patients, this disruption manifests as thyroid during the adjustment period
Kurtzhals, P., Flindt Kreiner, F
One of our trusted prescribers will review your answers to ensure that your treatment is safe and appropriate for your health needs